title: Profiles of inflammatory markers and lipoprotein subclasses in patients undergoing continuous ambulatory peritoneal dialysis.
abstract: BACKGROUND
  Patients undergoing continuous ambulatory peritoneal dialysis (CAPD) often have inflammation and dyslipidemia that accelerate to atherosclerosis. This study aimed to evaluate chronic inflammation and dyslipidemia in CAPD patients.
  
  
  METHODS
  We measured inflammatory markers and lipoprotein subclasses in 20 CAPD patients (12 men and 8 women, aged 59.5 ± 9.9 y) and 20 gender-matched controls. Lipoproteins were separated by high-performance liquid chromatography (HPLC) using an anion-exchange column.
  
  
  RESULTS
  High-sensitivity C-reactive protein and serum amyloid A protein (SAA) were higher among CAPD patients vs. controls (1.6 ± 2.2 vs. 0.8 ± 1.2 mg/l, p<0.05; 11.9 ± 12.8 vs. 4.5 ± 2.4 mg/l). HPLC analysis revealed that chylomicron, VLDL, and IDL cholesterol levels were higher among CAPD vs. controls. In contrast, HDL cholesterol was lower among CAPD patients vs. controls. In the subgroup analysis, SAA levels were significantly lower among patients receiving CAPD for >3 y than among controls. However, IDL cholesterol was consistently higher among CAPD patients vs. controls.
  
  
  CONCLUSIONS
  CAPD patients have chronic inflammation and dyslipidemia. IDL cholesterol is the only lipoprotein subclass that is consistently elevated regardless of CAPD duration. More attention should be paid to dyslipidemia in the management of the CAPD patients.
authors.affiliation: Department of Clinical Laboratory Medicine, Juntendo University Faculty of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan.
authors.forename: Mika
authors.initials: M
authors.lastname: Kon
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hirayama
authors.forename: Yuki
authors.initials: Y
authors.lastname: Horiuchi
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Ueno
authors.forename: Mayumi
authors.initials: M
authors.lastname: Idei
authors.forename: Yuriko
authors.initials: Y
authors.lastname: Fueki
authors.forename: Utako
authors.initials: U
authors.lastname: Seino
authors.forename: Shin
authors.initials: S
authors.lastname: Goto
authors.forename: Hiroki
authors.initials: H
authors.lastname: Maruyama
authors.forename: Noriaki
authors.initials: N
authors.lastname: Iino
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Fukushima
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Ohmura
authors.forename: Yuji
authors.initials: Y
authors.lastname: Hirowatari
authors.forename: Takashi
authors.initials: T
authors.lastname: Miida
mesh_terms: D000368:Aged; D015415:Biomarkers; D016022:Case-Control Studies; D002784:Cholesterol / Q000097:blood; D050171:Dyslipidemias / Q000175:diagnosis / Q000209:etiology; D005260:Female; D006801:Humans; D007249:Inflammation / Q000175:diagnosis* / Q000209:etiology; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*
chemical_list: D015415:Biomarkers; D008074:Lipoproteins; C030104:lipoprotein cholesterol; D002784:Cholesterol